Global Partners LP (GLP)
$
45.79
-0.18 (-0.39%)
Key metrics
Financial statements
Free cash flow per share
7.5483
Market cap
1.5 Billion
Price to sales ratio
0.0698
Debt to equity
2.9372
Current ratio
1.1829
Income quality
3.3022
Average inventory
506.5 Million
ROE
0.1553
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Global Partners LP is actively engaged in the purchasing, selling, gathering, blending, storing, and logistical transportation of a variety of petroleum products including gasoline, gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, and propane, catering to wholesalers, retailers, and commercial clients throughout the New England states, Mid-Atlantic region, and New York. The company operates a comprehensive Wholesale segment that supplies home heating oil, branded and unbranded gasoline, diesel, kerosene, residual oil, and propane to home heating oil retailers and wholesale distributors. Additionally, it aggregates crude oil via truck or pipeline across the mid-continent region of the United States and Canada, utilizing rail and barge transport to deliver to refiners. Its Gasoline Distribution and Station Operations segment services gasoline station operators and sub-jobbers with both branded and unbranded gasoline while managing networks of gasoline stations and convenience stores that offer car wash, lottery, and ATM services. Within its Commercial segment, the company provides unbranded gasoline, home heating oil, diesel, kerosene, residual oil, and bunker fuel to public sector entities, commercial clients, and industrial users, alongside custom blended fuels. As of December 31, 2021, Global Partners LP held a diverse portfolio consisting of 1,595 owned, leased, and supplied gasoline stations, of which 295 included directly operated convenience stores, and maintained 26 bulk terminals with a total storage capacity of 11.9 million barrels. The EBITDA is $389,394,000.00 a key indicator of the company's operational profitability, and the EBITDA ratio is 0.02 highlighting the company's operational efficiency. The operating expenses amount to $806,673,000.00 encompassing various operational costs incurred, while the weighted average number of diluted shares outstanding is 34,339,000.00 reflecting potential dilution effects. Furthermore, the weighted average number of shares outstanding is 33,840,000.00 highlighting the company's shareholder base. In terms of market positioning, the stock is affordable at $49.24 making it suitable for budget-conscious investors. However, it has a low average trading volume of 62,076.00 indicating lower market activity. With a market capitalization of $1,552,327,477.00 the company is classified as a small-cap player, which is significant in its respective field. It is a key player in the Oil & Gas Midstream industry, contributing significantly to the overall market landscape, and it belongs to the Energy sector, driving innovation and growth. This dynamic positioning within the market underscores the company's potential for future development and influence.
Is Global Partners LP (GLP) a good investment?
Investing in Global Partners LP (GLP) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bullish outlook. Always conduct your own research before investing.
What is Global Partners LP (GLP)'s stock forecast?
Analysts predict Global Partners LP stock to fluctuate between $43.20 (low) and $60 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Global Partners LP's market capitalization?
As of 2025-10-27, Global Partners LP's market cap is $1,552,327,477, based on 33,901,015 outstanding shares.
How does Global Partners LP compare to competitors like Exxon Mobil Corporation?
Compared to Exxon Mobil Corporation, Global Partners LP has a Lower Market-Cap, indicating a difference in performance.
Does Global Partners LP pay dividends?
Global Partners LP pays dividends. The current dividend yield is 5.91%, with a payout of $0.75 per share.
How can I buy Global Partners LP (GLP) stock?
To buy Global Partners LP (GLP) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for GLP. Place an order (Market, Limit, etc.).
What is the best time to invest in Global Partners LP?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Global Partners LP perform in the last earnings report?
Revenue: $17,163,566,000 | EPS: $3.18 | Growth: -15.65%.
Where can I find Global Partners LP's investor relations reports?
Visit https://www.globalp.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Global Partners LP?
You can explore historical data from here
What is the all-time high and low for Global Partners LP stock?
All-time high: $60 (2025-02-21) | All-time low: $19.45 (2021-08-19).
What are the key trends affecting Global Partners LP stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced a major intellectual property milestone: the Japanese Patent Office has issued a Notice of Allowance for the Company's ThermoStem® platform.
reuters.com
China's Innovent Biologics saidon Monday its GLP-1 injection led to more weight loss and better control of blood sugar in patients with diabetes than injectable semaglutide, the active ingredient in Novo Nordisk's diabetes and weight-loss medicines.
benzinga.com
West Pharmaceutical Services, Inc. (NYSE:WST) shares surged Thursday after the injectable pharmaceutical packaging and delivery systems company's third-quarter 2025 earnings surpassed analyst estimates.
cnbc.com
A closely watched pill from Novo Nordisk just scored an approval for slashing cardiovascular risks, while Mark Cuban gives Trump credit on drug prices.
seekingalpha.com
West Pharmaceutical Services earns a Buy rating with a $320 price target, reflecting ~18% upside with strong long-term growth prospects. WST's high-value product mix is expanding, driving margin growth through proprietary, high-margin offerings and regulatory stickiness. Surging demand for GLP-1 therapies and biologics underpins durable growth for WST's containment and delivery systems, reinforcing the investment thesis.
prnewswire.com
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of s mall m olecule GLP-1 receptor ( GLP-1R) a gonist ASC30 in 65 participants with obesity or overweight. - The u ltra-long-acting SQ depot treatment formulation of small molecule ASC30 demonstrated a 46-day observed half-life in participants with obesity in the Phase Ib study, supporting once-monthly administration.
seekingalpha.com
The market has overreacted to ABT's lowered FY2025 organic sales growth/narrowed adj. EPS, since the management continues to deliver robust numbers while building upon FY2024 outperformance. Much of its tailwinds are attributed to the robust demand for its diabetes care offerings across continuous glucose monitors and Adult Nutrition, thanks to the ongoing GLP-1 boom. ABT has also been driving renewed growth, with new launches generating "nearly $0.5 billion in sales this quarter and adding more than 100 basis points to organic sales growth."
youtube.com
Shares of Eli Lilly and Novo Nordisk came under pressure after President Trump said during an event at the White House that the administration is looking bring down prices of popular weight loss GLP-1s to $150 per month.
cnbc.com
Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration aims to cut the cost of brand name GLP-1 weight loss drugs to $150 per month, a fraction of their current list price. Centers for Medicare and Medicaid Administrator Dr. Mehmet Oz interjected and stressed that the administration has not yet agreed to GLP-1 price reductions with drugmakers.
247wallst.com
GLP-1 drugs propelled Novo Nordisk (NVO) and Eli Lilly (LLY) to record profits, with sales exceeding $20 billion amid skyrocketing demand. Both companies cut prices recently to expand access, but President Trump's vow threatens deeper reductions.
See all news
